2,5-Anhydro sugar diacid and 2,5-anhydro sugar diamine based C2 symmetric peptidomimetics as potential HIV-1 protease inhibitors

被引：26

作者：

Chakraborty, TK ^{[1
]}

Ghosh, S

Rao, MHVR

Kunwar, AC

Cho, H

Ghosh, AK

机构：

[1] Indian Inst Chem Technol, Hyderabad 500007, Andhra Pradesh, India

[2] Univ Illinois, Dept Chem, Chicago, IL 60607 USA

来源：

TETRAHEDRON LETTERS | 2000年 / 41卷 / 51期

关键词：

D O I：

10.1016/S0040-4039(00)01803-7

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

Conformationally constrained molecular frameworks of the 2,5-anhydro sugar diacid (9) and 2,5-anhydro sugar diamines (10, 11) were used to construct architecturally beautiful novel C-2 symmetric peptidomimetics 1-8. Although none of these compounds showed any significant HIV-I protease inhibitory activity, further refinements in design may lead to protease inhibitors based on these rigid carbohydrate-derived scaffolds. (C) 2000 Elsevier Science Ltd. All rights reserved.

引用

页码：10121 / 10125

页数：5

共 17 条

[1] Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors.: Use of L-mannaric acid as a peptidomimetic scaffold [J].

Alterman, M ;

Björsne, M ;

Mühlman, A ;

Classon, B ;

Kvarnström, I ;

Danielson, H ;

Markgren, PO ;

Nillroth, U ;

Unge, T ;

Hallberg, A ;

Samuelsson, B .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (20) :3782-3792

[2] Synthesis and conformational studies by peptidomimetics containing furanoid sugar amino acids an a sugar diacid [J].

Chakraborty, TK ;

Ghosh, S ;

Jayaprakash, S ;

Sharma, JARP ;

Ravikanth, V ;

Diwan, PV ;

Nagaraj, R ;

Kunwar, AC .

JOURNAL OF ORGANIC CHEMISTRY, 2000, 65 (20) :6441-6457

[3] Folded conformation in peptides containing furanoid sugar amino acids [J].

Chakraborty, TK ;

Jayaprakash, S ;

Diwan, PV ;

Nagaraj, R ;

Jampani, SRB ;

Kunwar, AC .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1998, 120 (49) :12962-12963

[4] Money matters - The marketplace of HIV/AID$ [J].

Cohen, J .

SCIENCE, 1996, 272 (5270) :1880-1881

[5] CARBOHYDRATES AND GLYCOCONJUGATES - EDITORIAL OVERVIEW [J].

DRICKAMER, K ;

DWEK, RA .

CURRENT OPINION IN STRUCTURAL BIOLOGY, 1995, 5 (05) :589-590

[6] Quantitative symmetry in structure-activity correlations:: The near C2 symmetry of inhibitor/HIV protease complexes [J].

Keinan, S ;

Avnir, D .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2000, 122 (18) :4378-4384

[7]

KEMPF DJ, 1994, METHOD ENZYMOL, V241, P334

[8] RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS [J].

LAM, PYS ;

JADHAV, PK ;

EYERMANN, CJ ;

HODGE, CN ;

RU, Y ;

BACHELER, LT ;

MEEK, JL ;

OTTO, MJ ;

RAYNER, MM ;

WONG, YN ;

CHANG, CH ;

WEBER, PC ;

JACKSON, DA ;

SHARPE, TR ;

ERICKSONVIITANEN, S .

SCIENCE, 1994, 263 (5145) :380-384

[9] Protease inhibitors: Current status and future prospects [J].

Leung, D ;

Abbenante, G ;

Fairlie, DP .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (03) :305-341

[10] Recent developments in HIV protease inhibitor therapy [J].

Molla, A ;

Granneman, GR ;

Sun, E ;

Kempf, DJ .

ANTIVIRAL RESEARCH, 1998, 39 (01) :1-23

← 1 2 →